<DOC>
	<DOC>NCT00129571</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.</brief_summary>
	<brief_title>Study of XL820 in Adults With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor Cancer for which standard therapies do not exist or are no longer effective Life expectancy of &gt; 3 months Adequate bone marrow, liver, and kidney function Willing to use accepted method of contraception during the course of the study Negative pregnancy test (females) Written informed consent Chemotherapy within 46 weeks of the start of treatment (depending on the therapy) Radiotherapy to more than 25% of bone marrow within 4 weeks of the start of treatment Investigational drug within 30 days of the start of treatment Subjects with known brain metastasis Uncontrolled medical disorder such as infection or cardiovascular disease Subjects known to be HIV positive Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>